ArticleScientific reports2025
Evaluation of MCAM expression in correlation with clinicopathological parameters of gastric cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MCAM (Melanoma Cell Adhesion Molecule) is an adhesion protein belonging to the immunoglobulin superfamily, which was identified as a melanoma-specific protein. It is now clear that it can also be found in other types of neoplasms, e.g. in the carcinoma of the prostate, breast, ovary and stomach. MCAM plays a major pro-migratory role in the vascular system, promoting metastases. Therefore the study objective was to immunohistochemically evaluate MCAM expression in gastric cancer as well as to examine the correlation with chosen clinical-histopathological parameters. The study has shown that positive expression of MCAM was observed in cancer cells in 42.5% and in stromal cells in 33.3% of patients. The expression was more frequently seen in low desmoplasia tumors. The positive expression was also associated with higher grade of Helicobacter pylori infection. No correlation was noted with the overall survival rate. The expression of MCAM in stroma showed no correlation with clinical-histopathological parameters and patients' survival. The assessment of MCAM expression is not a useful marker to identify tumor stage nor it is a prognostic factor of gastric cancer. However, this protein may contribute to the process of desmoplastic stroma formation and be involved in the mechanism of inflammatory reaction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.